888.552.6760 SCHEDULE A CONSULTATION

The information on this page was reviewed and approved by
Maurie Markman, MD, President, Medicine & Science at CTCA.

This page was updated on June 7, 2021.

Common breast cancer types

After skin cancer, breast cancer is the most common type of cancer diagnosed in women. About 284,200 cases will be diagnosed in 2021, according to the American Cancer Society (ACS). Men also may develop breast cancer, though it’s much more rare.

Breast cancer is classified into different types based on how the cells look under a microscope. Most breast cancers are carcinomas, a type of cancer that begins in the linings of most organs.

Ductal carcinoma in situ (DCIS)

 

DCIS is the most common type of noninvasive breast cancer, with about 60,000 new cases diagnosed in the United States each year. About one in every five new breast cancer cases is ductal carcinoma in situ.

Also called intraductal carcinoma or stage 0 breast cancer, it’s considered a noninvasive breast cancer. With DCIS, abnormal and cancerous cells haven’t spread from the ducts into nearby breast tissue nor anywhere else, such as the lymph nodes.

DCIS is divided into several subtypes, mainly according to the appearance of the tumor. These subtypes include micropapillary, papillary, solid, cribriform and comedo.

Patients with ductal carcinoma in situ are typically at higher risk for seeing their cancer return after treatment, although the chance of a recurrence is less than 30 percent. Most recurrences occur within five to 10 years after the initial diagnosis and may be invasive or noninvasive. DCIS also carries a heightened risk for developing a new breast cancer in the other breast. A recurrence of ductal carcinoma in situ would require additional treatment.

The type of therapy selected may affect the likelihood of recurrence. Treating DCIS with a lumpectomy (breast-conserving surgery), and without radiation therapy, carries a 25 percent to 35 percent chance of recurrence. Adding radiation therapy to the treatment decreases this risk to about 15 percent. Currently, the long-term survival rate for women with ductal carcinoma in situ is nearly 100 percent.

Invasive ductal carcinoma (IDC)

Sometimes, ductal carcinoma can become an invasive cancer. With invasive ductal carcinoma, cancer spreads from a milk duct, where it originates, into nearby tissue and lymph nodes. From there, it may spread, or metastasize, to other parts of the body, such as the bones and distant organs. Cancerous cells travel and spread through the lymph system (which is part of the immune system) or bloodstream.

About eight in 10 invasive breast cancers are invasive ductal carcinoma, according to the ACS.

Surgery typically is the first treatment for IDC. The goal of this treatment is to remove the cancer from the breast with a lumpectomy or mastectomy. The type of surgery recommended depends on factors such as the tumor’s location and size and whether more than one area in the breast has been affected. For patients with ductal carcinoma, long-term systemic treatment with tamoxifen is recommended to prevent recurrence.

Lobular carcinoma

Among the invasive breast cancers, about 10 percent are invasive lobular carcinomas, or ILC. This cancer starts in the breast’s milk-producing glands, which are called lobules, and may spread to other parts of the body. About 20 percent of women with ILC have cancer in both breasts, according to the ACS.

The treatment options for invasive lobular carcinoma include localized approaches such as surgery and radiation therapy that treat the tumor and the surrounding areas, as well as systemic treatments such as chemotherapy and hormonal or targeted therapies that travel throughout the body to destroy cancer cells that may have spread from the original tumor.

Invasive lobular carcinoma (ILC)

Among the invasive breast cancers, about 10 percent are invasive lobular carcinomas, or ILC. This cancer starts in the breast’s milk-producing glands, which are called lobules, and may spread to other parts of the body. About 20 percent of women with ILC have cancer in both breasts, according to the ACS.

The treatment options for invasive lobular carcinoma include localized approaches such as surgery and radiation therapy that treat the tumor and the surrounding areas, as well as systemic treatments such as chemotherapy and hormonal or targeted therapies that travel throughout the body to destroy cancer cells that may have spread from the original tumor.

Expert
cancer care

IS ONE CALL AWAY.
APPOINTMENTS IN AS LITTLE
AS 24 HRS.

CALL NOW: 888-552-6760